UPDATE - Scipher Medicine Welcomes Sam Davis as General Counsel
September 24, 2021 12:00 ET
|
Scipher Medicine Corporation
WALTHAM, Mass., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Scipher Medicine, a precision immunology company matching patients with their most effective therapies, today announced the appointment of Sam A....
Scipher Medicine Welcomes Sam Davis as General Counsel
September 24, 2021 09:00 ET
|
Scipher Medicine Corporation
WALTHAM, Mass., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Scipher Medicine, a precision immunology company matching patients with their most effective therapies, today announced the appointment of Sam A....
Scipher Medicine Welcomes John Strumbos as Chief Financial Officer
September 22, 2021 10:50 ET
|
Scipher Medicine Corporation
WALTHAM, Mass., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Scipher Medicine, a precision immunology company matching patients with their most effective therapies, today announced the appointment of John...
Ventegra Partners with Scipher Medicine For Patient-Centric Approach To Improve Outcomes and Lower Costs for Rheumatoid Arthritis Care
September 16, 2021 08:00 ET
|
Scipher Medicine Corporation
WALTHAM, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Scipher Medicine, a precision immunology company matching patients with their most effective therapy, today announced a partnership with Ventegra,...
Scipher Medicine Increases Patient Access for Prismra® by Expanding Intended Use in Autoimmune Patients
July 29, 2021 09:22 ET
|
Scipher Medicine Corporation
Expanded intended use for the blood test validated in Network-004 study.Now, most rheumatoid arthritis patients can be tested at any point in their clinical journey.Test enables providers to identify...
Scipher Medicine Announces PrismRA® Met Primary and Secondary Endpoints in Prospective Observational Study Predicting Inadequate Response to World’s Largest-Selling Drug Class
June 24, 2021 08:00 ET
|
Scipher Medicine Corporation
Blood Test Predicts TNFi Response in Patients Both Naïve to and Experienced with TherapyProviders Can Access Patient-Specific Data for Optimized Therapy Selection WALTHAM, Mass., June 24, 2021 ...
Scipher Medicine Presents New Data at the European League Against Rheumatism (EULAR) 2021 Further Validating PrismRA® Test
June 15, 2021 08:00 ET
|
Scipher Medicine Corporation
Molecular signature test predicts likelihood of non-response to adalimumab or etanercept, two of the world’s most expensive medications, in an independent validation cohort PrismRA demonstrates a more...
Scipher Medicine and Leading Medical Researchers in Network and Data Science Compress Time to Identify COVID-19 Treatments From Years to Months
June 08, 2021 08:00 ET
|
Scipher Medicine Corporation
Study demonstrates Scipher Medicine’s ability to analyze patient data to identify novel treatments.Scipher will focus on pharma collaborations in autoimmune diseases. WALTHAM, Mass., June 08, 2021 ...